Industry

Yuvezzi for presbyopia now available in US

Healio Optometry2d ago1 min read

Editor’s note: This is a developing story. Please check back soon for updates.Yuvezzi, an eye drop for the treatment of presbyopia, is now available in the U.S.According to a press release from Tenpoint Therapeutics, patients can fill prescriptions from eye care professionals for Yuvezzi (carbachol 2.75%/brimonidine tartrate 0.1% ophthalmic solution) through the company’s e-pharmacy partner, PHILRx, as well as local retail pharmacies.Yuvezzi is the first FDA-approved eye drop that uses two active ingredients to improve visual acuity and depth of focus: carbachol, which constricts the iris

Read full article on Healio Optometry

AI Summary

Quick Take

Yuvezzi (carbachol 2.75%/brimonidine tartrate 0.1%), the first FDA-approved dual-active ingredient eye drop for presbyopia, is now commercially available in the United States. Developed by Tenpoint Therapeutics, the solution can be prescribed by eye care professionals and filled through the PHILRx e-pharmacy platform or local retail pharmacies.

Why It Matters

The pharmacological treatment of presbyopia is a rapidly evolving space, but early entries into the market faced challenges with duration of effect and side profiles like brow ache. Yuvezzi’s combination of a miotic with an alpha-2 agonist represents a strategic attempt to optimize the 'pinhole effect' while potentially mitigating some of the vasodilation-related side effects seen with monotherapy. For practices, this adds a new tool for emmetropic presbyopes who are increasingly vocal about wanting to reduce their reliance on reading glasses.

Key Details

Yuvezzi is a fixed-dose combination of carbachol 2.75% and brimonidine tartrate 0.1%.
It is the first FDA-approved presbyopia drop to utilize two active ingredients to improve visual acuity and depth of focus.
The carbachol component functions as a miotic, constricting the iris to create a pinhole effect for near tasks.
Distribution is handled through a partnership with PHILRx e-pharmacy as well as traditional retail pharmacy channels.
The product is manufactured and brought to market by Tenpoint Therapeutics.

Practice Implications

Clinicians should consider Yuvezzi for presbyopic patients who have not achieved desired results with single-agent miotics. When transitioning patients to this dual-action drop, practitioners should monitor for traditional miotic side effects and educate patients on the specific benefits of the carbachol-brimonidine combination for depth of focus.

Who's Affected

OptometristsOphthalmologistsPractice OwnersPresbyopic Patients

What's Next

As the product enters widespread clinical use, practitioners will be looking for real-world data regarding the duration of the near-vision effect and patient tolerability. Further updates from Tenpoint Therapeutics are expected as the commercial rollout expands across the U.S. market.

AI-generated summary — always read the original source for full context

Discussion

No comments yet. Be the first to share your thoughts.